Valuation: Roche Holding AG

Market Cap 294B 358B 315B 270B 505B 34,303B 517B 3,483B 1,362B 16,975B 1,345B 1,315B 58,681B P/E 2026 *
20.4x
P/E 2027 * 18.1x
Enterprise Value 304B 371B 326B 279B 523B 35,558B 536B 3,611B 1,412B 17,595B 1,394B 1,364B 60,827B EV / Sales 2026 *
4.86x
EV / Sales 2027 * 4.55x
Free-Float
88.78%
Yield 2026 *
2.72%
Yield 2027 * 2.78%
1 day+12.16%
Current month+0.48%
6 months-5.69%
Current year-1.29%
Current year 311.6
Extreme 311.6
377
1 year 221.3
Extreme 221.3
377
3 years 212.3
Extreme 212.3
377
5 years 212.3
Extreme 212.3
404.1
10 years 202.23
Extreme 202.231
404.1
Manager TitleAgeSince
Chief Executive Officer 51 14/03/2023
Director of Finance/CFO 59 05/06/2011
Chief Operating Officer - 30/09/2025
Director TitleAgeSince
Director/Board Member 68 31/12/1995
Chairman 59 14/03/2023
Director/Board Member 73 02/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 359B
-0.33%+4.81%+59.77%+168.17% 1,089B
+0.14%+4.77%+59.31%+59.86% 643B
+1.08%+5.27%+39.45%+78.27% 465B
-0.51%+3.51%+36.97%+42.46% 303B
+1.50%+3.40%+17.71%+17.41% 267B
+0.79%+5.81%-2.55%-38.10% 226B
-0.82%+6.82%+28.80%+66.99% 212B
-0.44%+2.59%+17.06%+75.62% 167B
+0.06%+1.91%+4.09%-29.85% 144B
Average +1.33%+3.90%+28.96%+48.98% 390.62B
Weighted average by Cap. +1.22%+4.40%+41.65%+82.31%

Financials

2026 *2027 *
Net sales 62.64B 76.38B 67.11B 57.49B 108B 7,316B 110B 743B 291B 3,620B 287B 281B 12,515B 65.47B 79.82B 70.14B 60.09B 112B 7,646B 115B 776B 304B 3,783B 300B 293B 13,079B
Net income 14.58B 17.78B 15.62B 13.38B 25.05B 1,703B 25.67B 173B 67.61B 843B 66.74B 65.29B 2,913B 16.36B 19.95B 17.53B 15.02B 28.11B 1,911B 28.81B 194B 75.89B 946B 74.91B 73.28B 3,269B
Net Debt 10.74B 13.1B 11.51B 9.86B 18.46B 1,255B 18.91B 127B 49.83B 621B 49.18B 48.12B 2,146B 3.96B 4.83B 4.25B 3.64B 6.81B 463B 6.98B 46.99B 18.38B 229B 18.14B 17.75B 792B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
29/07/26 CHF 323.90 0.00% 532
28/07/26 CHF 323.90 0.00% 4,250
27/07/26 CHF 323.90 0.00% 6,381
24/07/26 CHF 323.90 0.00% 84,268
23/07/26 CHF 323.90 0.00% 15,316
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
367.90CHF
Average target price
363.92CHF
Spread / Average Target
-1.08%

Quarterly revenue - Rate of surprise